UTMB will collaborate with HDT Bio Corp. and the National Institute of Allergy and Infectious Diseases’ Rocky Mountain Labs to develop vaccines against Crimean-Congo hemorrhagic fever virus (CCHFV) and Nipah virus (NiV) The 5-year $59M prototype project will develop...

SEATTLE--HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced today it has been selected to join Blue Knight, a collaboration between Johnson & Johnson Innovation – JLABS (‘JLABS’) and the Biomedical Advanced Research and...

SEATTLE, WA (November 1, 2022) – HDT Bio Corp., a developer of immunotherapies for infectious diseases and oncology, announced today CEO Steven Reed will give a corporate presentation on Nov. 8, 3 pm, Fourth Floor, (Adams) at the BioFuture Investor Conference at the...

The company’s saRNA vaccine technology, using its proprietary LION™ delivery system, already has proved successful in development of COVID-19 vaccines  SEATTLE, WA (August 23, 2022) – HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases,...

The antiviral product, HDT-201, will utilize company’s RNA/LION™ platform technology and ultimately will be available to the public. SEATTLE, WA (August 8, 2022) – HDT Bio Corp., a developer of immunotherapies for infectious diseases and oncology, announced today it...

SEATTLE, WA (July 20, 2022) – HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced today it has been awarded a nearly $1.5M Phase 2 Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and...

Next-generation RNA technology can be safer, more effective at lower doses than current mRNA COVID-19 vaccines. Proprietary LION™ delivery system provides stability at refrigerator temperature SEATTLE--(June 29, 2022) -- Indian regulators have issued an Emergency Use...

HDT Bio’s technology uses self-replicating RNA and has the potential to deliver a COVID-19 vaccine targeting multiple variants, providing broad protection from disease and reduced transmission from breakthrough infections Seattle, WA, (April 5, 2022) – HDT Bio Corp.,...

HDT’s technology offers simpler manufacturing, easier deployment, and requires much lower doses than existing COVID-19 RNA vaccines, enabling global supply.  Vaccine targets Beta variant; has demonstrated effectiveness against other variants;  will be evaluated as...

HDT Bio’s RNA-based vaccine offers simpler manufacturing, easier deployment without the need for ultra-low freezers, and requires vastly lower dosing than current RNA COVID-19 vaccines SEATTLE & SALVADOR, Brazil--January 17, 2022--HDT Bio Corp., a U.S. developer...